National Institute for Health and Clinical Excellence (NICE)
NICE and PHE publish comprehensive draft guideline to tackle the health burden of smoking
Healthcare staff should give clear and up-to-date information on e-cigarettes to people who are interested in using them to stop smoking, according to draft NICE guideline recommendations out for consultation today. NICE worked with Public Health England to develop this guideline
The evidence shows that nicotine-containing e-cigarettes can help people to stop smoking and are similarly effective to other cessation options such as a combination of short- and long-acting nicotine replacement therapy (NRT). The expert committee agreed that people should be able to use e-cigarettes as one of several options to support smoking cessation, if they so choose.
The draft recommendations advise that, combined with behavioural support, the option of either a combination of short- and long-acting NRT or nicotine-containing e-cigarettes are more likely to result in people successfully stopping smoking.
The draft recommendations state that people should be advised on where to find information on nicotine-containing e-cigarettes, that e-cigarettes are substantially less harmful than smoking, but that the long-term health effects of e-cigarettes are still uncertain. People should also be advised on how to use e-cigarettes correctly and be informed that they should stop smoking completely if they decide to start using nicotine-containing e-cigarettes.
The committee also made recommendations for further research into both short and long-term health effects from e-cigarettes, and whether there are specific health effects related to e-cigarette use in certain groups such as pregnant women and young people.
The draft guideline also recommends that, in addition to pharmacological and behavioural support, pregnant women who are referred to a stop-smoking service should be offered vouchers to encourage them to stop smoking. Vouchers should only be provided when smoking abstinence is validated by a biochemical test such as a carbon monoxide test. Providers of stop-smoking support services should ensure these vouchers cannot be used to purchase products, such as cigarettes or alcohol, that are harmful in pregnancy.
Evidence shows that this financial incentive approach is both effective and cost effective, and that voucher incentives are seen as acceptable to many pregnant women and healthcare providers. For every 1000 pregnant women offered vouchers, an additional 177 mothers would stop smoking.
Dr Paul Chrisp, director of NICE’S Centre for Guidelines, said: “These draft guideline recommendations are a renewed effort to reduce the health burden of smoking and to encourage and support people to give up smoking. Smoking continues to take a huge toll on the health of the nation and accounts for approximately half the difference in life expectancy between the richest and poorest in society. It is therefore vitally important that we reduce the level of smoking in this country.
“We know that around 10% of women are known to be smokers at the time of giving birth and, given the significant health effects of smoking on both mothers and babies, it is clear that further efforts are required to encourage this group to give up smoking.
“We need to use every tool in our arsenal to reduce smoking rates, including education, behavioural support, financial incentives, and e-cigarettes if people are interested in using them. Combined, we hope that people who smoke will feel enabled to give up tobacco products once and for all.”
Rosanna O'Connor, Director Drugs, Alcohol, Tobacco and Justice at Public Health England, said:
“This new guidance offers a welcome ‘how-to guide’ for reducing the harm caused by smoking including helping smokers to quit and preventing a new generation of smokers from starting. This consultation is an important opportunity for all our partners to help shape these recommendations.”
There are currently no medicinally licensed e-cigarettes. E-cigarettes that contain or could contain nicotine in the form of e-liquid are covered under the Tobacco and Related Products Regulations 2016 and need to be notified to the Medicines and Healthcare products Regulatory Agency (MHRA). Other devices such as disposable e-cigarettes that do not contain nicotine, and 0% nicotine e-liquids, are regulated under the General Product Safety Regulations 2005.
This draft guideline is a consolidation and update of eight previous guidelines on smoking. The draft guideline is out for consultation until 6 August 2021 and can be commented upon here.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
Professor Gillian Leng to retire from NICE09/09/2021 14:15:00
Professor Leng has spent more than 20 years working at NICE.
NICE draft guidance recommends apalutamide for treating prostate cancer08/09/2021 12:20:00
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
Sharing evidence with NICE is part of a broader approach to help Cochrane to identify priority reviews02/09/2021 11:15:00
Toby Lasserson, deputy editor in chief at Cochrane, writes about a new collaborative agreement with NICE, how it will work and what it means for the health service.
NICE approves ground-breaking cholesterol-lowering drug inclisiran01/09/2021 13:05:00
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke
NICE and Cochrane sign collaborative agreement to deliver ‘living’ guideline recommendations01/09/2021 12:05:00
NICE and Cochrane have today (01st September 2021) signed a collaborative agreement which will help to deliver ‘living’ recommendations across the NICE guideline portfolio.
NICE announces next steps for ME/CFS guideline31/08/2021 09:15:00
NICE recognises the importance to patients of the updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) and is keen to move forwards as quickly as possible.